Renée Aguiar-Lucander

Renée Aguiar-Lucander

Directeur Général chez HANSA BIOPHARMA AB

Fortune : 670 362 $ au 30/06/2026

64 ans
Health Technology
Commercial Services
Finance

Profil

Renée Julie Elisabet Aguiar-Lucander is currently Chief Executive Officer at Hansa Biopharma AB since 2025.
Also holds Chairman positions at Simparel, Inc. and Exenta, Inc. Serves as Director at Inventiva SA and Egalet A, Independent Director at AC Immune SA, and Director at Ral Capital Ltd. (United Kingdom), all starting in 2025 or ongoing.
Formerly Chief Executive Officer at Calliditas Therapeutics AB from 2017 to 2025.
Previously held roles including Chairman at EnXray Ltd., Director at SpineVision SAS, ImpactRx, Inc., NsGene A, Onyvax Ltd., Sophion Bioscience A, BioSilta Ltd., Danish BioVenture General Partner ApS, Calliditas Therapeutics France SAS, and SciBase Holding AB. Served as Independent Director at Zyla Life Sciences LLC, MedCap AB, and SciBase Holding AB. Held Independent Non-Executive Director position at Newron Pharmaceuticals SpA from 2006 to 2011.
Non-Executive Director at Pulmagen Therapeutics (Synergy) Ltd. Independent Director at Egalet Ltd. in 2013.
Managing Director-Corporate Finance at Lehman Brothers, Inc. (Milan Branch) in 2003.
Partner at 3i Group Plc and 3i Venture Capital.
Chief Operating Officer & Partner at Omega Fund Management UK LLP.
Education includes an MBA from INSEAD and undergraduate studies at Stockholm School of Economics.

Détentions connues dans des sociétés publiques

SociétéDateNombre d'actionsValorisationDate de valorisation
28/07/2025 150 000 ( 0,15 % ) 548 658 $ 30/06/2026
11/06/2026 51 136 ( 0,05 % ) 121 704 $ 30/06/2026

Postes actifs de Renée Aguiar-Lucander

SociétésPosteDébut
HANSA BIOPHARMA AB Directeur Général 24/04/2025
INVENTIVA Directeur/Membre du Conseil 22/05/2025
AC IMMUNE SA Directeur/Membre du Conseil 19/06/2025
Ral Capital Ltd. (United Kingdom)
Directeur/Membre du Conseil -
Président -
Président -
Directeur/Membre du Conseil -

Anciens postes connus de Renée Aguiar-Lucander

SociétésPosteFin
CALLIDITAS THERAPEUTICS AB Directeur Général 01/01/2025
ZYLA LIFE SCIENCES Directeur/Membre du Conseil 10/06/2015
░░░░░░ ░░░░ ░░░░░░░░░░ ░░░░░░░░░░
░░ ░░░░░░░ ░░░░░░░ ░░░░░░░ ░░░░░░ ░░░░░░░░ ░░░░░░░░░░
░░░░░░ ░░░░░░░░░ ░░░░ ░░░░░░ ░░░░░░░ ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ ░░░░░░░░░░
Voir l'expérience en détail de Renée Aguiar-Lucander

Formation de Renée Aguiar-Lucander

Expériences
Fonctions occupées

Actives

Inactives

Sociétés cotées

Entreprise privées

Relations

33

Relations au 1er degré

29

Entreprises liées au 1er degré

Homme

Femme

Administrateurs

Exécutifs

Sociétés liées

Entreprise privées29

Miscellaneous

Health Technology

Commercial Services

Health Technology

Health Technology

Commercial Services

Consumer Services

Health Technology

Consumer Services

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Commercial Services

Finance

Health Technology

Finance

Health Technology

Commercial Services

Health Technology

Omega Fund Management UK LLP

Finance

Health Technology

Health Technology

Technology Services

Commercial Services

Technology Services

Ral Capital Ltd. (United Kingdom)

  1. Bourse
  2. Insiders
  3. Renée Aguiar-Lucander
🔇